Closing
Do other lipid agents improve all-cause mortality versus placebo?
Mostly studied in coronary & atherosclerotic disease.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, one result, not yet repeated.
NoUnsureYes
- Belief
- 0.50 (range 0.25–0.70)
- Trials for
- 1
- Trials against
- 0
- Inconclusive
- 2
Already under way
- A Registry-based Randomized Controlled Trial of Moderate-intensity Statin Therapy vs. Individualized Low-density Lipoprotein Cholesterol Target-based Therapy…NCT07359105 · recruiting · started 2026
- Utilizing Lipid-lowering Therapy With Moderate-intensity Statin Plus Ezetimibe in Chronic Kidney Disease Patients With Concomitant Atherosclerotic…NCT07524101 · recruiting · started 2026
- Comparing the Moderate Intensity STatin With Ezetimibe COmbination TheraPy With High Intensity Statin Monotherapy on Coronary PLAQUE StabilizationNCT06767345 · recruiting · started 2025
- Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in RussiaNCT06858332 · recruiting · started 2025
- Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)NCT06649240 · recruiting · started 2024
The evidence so far
- Registered trials
- 23
- With posted results
- 4
- Published papers
- 8
Of 6 decided analyses: 5 favor other lipid agents, 1 find no difference, 0 favor the comparator.
Papers
- Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia.Trial report · 2026
- All-Cause Mortality and Cardiovascular Death between Statins and Omega-3 Supplementation: A Meta-Analysis and Network Meta-Analysis from 55 Randomized Controlled Trials.Meta-analysis / systematic review · 2020
- Safety and efficacy of ezetimibe: A meta-analysis.Meta-analysis / systematic review · 2015
- Fibrates for primary prevention of cardiovascular disease events.Meta-analysis / systematic review · 2016
- Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials.Meta-analysis / systematic review · 2015
- Role of Niacin in Current Clinical Practice: A Systematic Review.Meta-analysis / systematic review · 2017
Trials
- A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)NCT00202878 · 4 posted results
- Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients: a Randomized Crossover TrialNCT06381947
- ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cARTNCT01683656
- ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)NCT00397657
- Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering TherapyNCT00715273 · 1 posted result
- Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)NCT06649240
- Comparing the Moderate Intensity STatin With Ezetimibe COmbination TheraPy With High Intensity Statin Monotherapy on Coronary PLAQUE StabilizationNCT06767345
- AIM HIGH: Niacin Plus Statin to Prevent Vascular EventsNCT00120289 · 4 posted results